24hr Effects of Tiotropium Bromide in Tetraplegia

Completed · Phase 2 · Has a placebo group

Conditions studied: Spinal Cord Injury

In brief

Respiratory complications are the leading cause of death during the initial year after acute SCI, and the third leading cause of death thereafter. Complete or partial loss of respiratory muscle innervations in individuals with cervical and high thoracic injuries leads to inadequate ventilation and inability to effectively clear secretions, often prompting supportive ventilation following initial injury. Development of atelactasis, pneumonias and respiratory failure are the most common respiratory complications observed during the acute phase of injury. It is well known that a restrictive ventilatory defect, dependent upon the level and completeness of injury, is apparent in individuals with chronic cervical SCI. Respiratory functional impairment might be further compromised in these individuals, the majority of whom share many aspects of obstructive airway physiology commonly associated with asthma. The asthma-like features that individuals with chronic cervical SCI demonstrate have been hypothesized to be due to overriding cholinergic airway tone carried by intact vagal (parasympathetic) nerve fibers arising from the brainstem, whereas sympathetic innervations is interrupted at the level of the upper thoracic spinal cord. Whether airway narrowing and AHR in chronic cervical SCI is also related to chronic airway inflammation is unknown, although it is conceivable that repeated respiratory infections or, possibly, a neurogenic component, could contribute to chronic airway inflammation. Therefore, the investigators aim to assess how long-acting bronchodilator (tiotropium bromide) affects various indices of lung function, including: pulmonary function tests, levels of inflammation and cough strength across 24 hours after receiving study drug. Results will be analyzed for baseline, 1 hour, 3 hours, 20 hours and 24 hours post drug inhalation for both active medication and non-active placebo.

Key facts

Study ID

NCT02586649

Run by

James J. Peters Veterans Affairs Medical Center

People needed

10

Starts

2014-07-01

Expected to finish

2019-12-01

Last updated by the study team

2020-09-16

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Chronic Spinal Cord Injury (>1 year post-injury)
• Stable tetraplegia (level of injury C3-C8, non-ventilator dependent)
• Male or female between the ages 18-65

You may not qualify if…

• Smoking, active or history of smoking during last 6 months;
• Ventilator dependent;
• Known history of asthma, COPD or inflammatory disease during lifetime;
• Active or recent (within 3 months) respiratory infection;
• Use of medications known to affect the respiratory system;
• Use of medications known to alter airway caliber
• Uncontrolled hypertension;
• Glaucoma or cataracts;
• History of milk protein allergy
• Pregnant or trying to become pregnant
• Lack of mental capacity to give informed consent

Where it is running

• James J Peters VA Medical Center — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.